“Being able to share the important results of this clinical trial with the world through publication in JEADV is a privilege and highlights the clinical significance of our work with HyBryte™. I have seen firsthand the promise this therapy can offer patients and was happy to build upon our knowledge working with HyBryte™ in a clinical setting reflective of real-world use.”
Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group, Fairport, NY, and Principal Investigator for the compatibility study and Leading Enrolling Investigator in Soligenix’s FLASH study, said that the publication highlights the positive clinical results from the study
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial | Hematology | JAMA Dermatology | JAMA Network
This randomized clinical trial of hypericin ointment, 0.25%, for patients with early-stage mycosis fungoides−cutaneous T-cell lymphoma examines lesion
Read More
“The ease at which photodynamic therapy with HyBryte™ is conducted and the outstanding safety profile we continue to see as demonstrated by the systemic exposure and cardiac results reviewed in this paper makes me very excited for its potential future clinical use."
Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group